Darlene Noci, ALM, currently serves as the Chief Development Officer at Nuvalent Inc Class A, a position she has held since joining the company. With an extensive background in biopharmaceutical development, Noci has become a pivotal figure in driving Nuvalent's mission to develop novel therapies for cancer patients. Her role involves overseeing the strategic development and execution of the company's clinical programs, ensuring that Nuvalent remains at the forefront of innovative cancer treatment solutions. Before her tenure at Nuvalent, Noci amassed a wealth of experience in the biopharmaceutical industry. She holds an ALM degree from Harvard University, which has equipped her with a strong foundation in both the scientific and managerial aspects of drug development. Throughout her career, she has been instrumental in leading cross-functional teams, managing clinical trials, and navigating the complex regulatory landscape. Her achievements include successfully advancing multiple drug candidates through various stages of development, from preclinical to late-stage clinical trials, demonstrating her ability to bring innovative therapies from concept to market. At Nuvalent, Noci's leadership has been crucial in advancing the company's pipeline of targeted therapies. Her strategic vision and hands-on approach have fostered a collaborative environment that accelerates the development process while maintaining a focus on patient needs. Under her guidance, Nuvalent has made significant strides in its mission to transform the treatment landscape for cancer patients, solidifying its position as a leader in the field. Noci's dedication to excellence and innovation continues to drive Nuvalent's growth and success.